Emerging Treatment and Management Paradigms In PsA

Emerging Treatment and Management Paradigms In PsA is organized by Cleveland Clinic Center for Continuing Education and would be held during Sep 05, 2017 - Sep 05, 2019.

Target Audience:
The online series is designed for rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, and associated allied health practitioners, including nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and inflammatory disorders.

Accreditation:
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Description:
Biologic Therapies VII: Precision Medicine in the Biologic Era online series brings together world leaders in immune-based therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics.

This webcast will review the latest treatment approaches for PsA and the data to support commonly used medications as well as newly approved or emerging therapies.

Learning Objectives:
• Review PsA treatment approaches with the currently most commonly used medications, methotrexate and TNFs.
• Describe treat-to-target goal and tight control outcomes in PsA.
• Review rationale and treatment data for recently approved medications, ustekinumab, apremilast, and secukinumab.
• Review data from ACR 2016 for emerging PsA treatments, including new IL17, IL23, JAK, T cell, and dual mechanism inhibitors.

Additional details will be posted as soon as they are available.